Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 ...

In particular, our expectations regarding Kisqali in combination with an AI could be affected ... in the MONALEESA (ML) trials. Poster presented at the European Society of Medical Oncology Congress; ...

Hundreds of posters have appeared on billboards across Italy this summer, bearing the slogan: “Russia is not our enemy” and depicting a handshake in the colors of the Italian and Russian flags.

Basel, September 17, 2024 – Novartis today announced that the US Food and Drug Administration (FDA) has approved Kisqali ® (ribociclib) in combination with an aromatase inhibitor (AI ...

The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It targets high-risk HR-positive, HER2-negative stage II and III patients ...

The US Food and Drug Administration (FDA) has approved a label expansion for Novartis’s Kisqali (ribociclib), allowing it to be used as an add-on therapy in early breast cancer patients.

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free benefits in a breast cancer subset. For patients with hormone receptor ...

Kisqali has been FDA-approved with an aromatase inhibitor as postsurgical treatment for some with early breast cancer at a high risk of recurrence. The Food and Drug Administration (FDA) has approved ...